Kalpit Patel
Stock Analyst at Wolfe Research
(2.13)
# 3,146
Out of 5,182 analysts
78
Total ratings
44.23%
Success rate
-4.8%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kalpit Patel
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SLNO Soleno Therapeutics | Downgrades: Peer Perform | n/a | $52.63 | - | 2 | Apr 7, 2026 | |
| GMAB Genmab | Initiates: Outperform | $32 | $28.25 | +13.27% | 1 | Mar 27, 2026 | |
| OLMA Olema Pharmaceuticals | Initiates: Peer Perform | n/a | $16.10 | - | 1 | Mar 27, 2026 | |
| KRYS Krystal Biotech | Initiates: Peer Perform | n/a | $259.00 | - | 1 | Mar 27, 2026 | |
| ONC BeOne Medicines AG | Initiates: Outperform | $340 | $309.66 | +9.80% | 1 | Mar 27, 2026 | |
| CORT Corcept Therapeutics | Upgrades: Peer Perform | n/a | $41.91 | - | 2 | Mar 26, 2026 | |
| AVBP ArriVent BioPharma | Maintains: Buy | $37 → $45 | $25.46 | +76.75% | 2 | Mar 23, 2026 | |
| KYMR Kymera Therapeutics | Maintains: Buy | $80 → $117 | $85.05 | +37.57% | 6 | Dec 22, 2025 | |
| PDSB PDS Biotechnology | Maintains: Buy | $5 → $3 | $1.08 | +177.78% | 6 | Nov 25, 2025 | |
| ORIC ORIC Pharmaceuticals | Initiates: Peer Perform | n/a | $10.15 | - | 1 | Nov 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Peer Perform | n/a | $14.93 | - | 1 | Nov 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Peer Perform | n/a | $19.95 | - | 1 | Nov 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Peer Perform | n/a | $114.83 | - | 1 | Nov 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Peer Perform | n/a | $19.67 | - | 1 | Nov 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $42 | $49.96 | -15.93% | 1 | Nov 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $75 | $96.43 | -22.22% | 1 | Nov 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $110 | $117.14 | -6.10% | 1 | Nov 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $12 | $5.17 | +132.11% | 6 | Jul 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $17 → $14 | $4.94 | +183.40% | 7 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $20 → $24 | $29.20 | -17.81% | 6 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5.5 → $3.5 | $1.67 | +109.58% | 4 | Feb 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 → $9 | $5.31 | +69.49% | 4 | Jan 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $4.59 | +117.86% | 1 | Jan 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $85 → $40 | $9.80 | +308.16% | 2 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $3 | $2.75 | +9.09% | 2 | Jun 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $25 → $20 | $14.95 | +33.78% | 3 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $90 → $30 | $4.10 | +631.71% | 1 | Dec 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $34 → $36 | $24.44 | +47.30% | 2 | Jul 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $270 → $90 | $1.39 | +6,374.82% | 3 | Nov 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $21 → $18 | $2.72 | +561.76% | 2 | Sep 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $6 → $5 | $1.13 | +342.48% | 2 | Jul 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $240 → $100 | $11.04 | +805.80% | 1 | Jan 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $75 | $35.09 | +113.74% | 2 | Sep 3, 2021 |
Soleno Therapeutics
Apr 7, 2026
Downgrades: Peer Perform
Price Target: n/a
Current: $52.63
Upside: -
Genmab
Mar 27, 2026
Initiates: Outperform
Price Target: $32
Current: $28.25
Upside: +13.27%
Olema Pharmaceuticals
Mar 27, 2026
Initiates: Peer Perform
Price Target: n/a
Current: $16.10
Upside: -
Krystal Biotech
Mar 27, 2026
Initiates: Peer Perform
Price Target: n/a
Current: $259.00
Upside: -
BeOne Medicines AG
Mar 27, 2026
Initiates: Outperform
Price Target: $340
Current: $309.66
Upside: +9.80%
Corcept Therapeutics
Mar 26, 2026
Upgrades: Peer Perform
Price Target: n/a
Current: $41.91
Upside: -
ArriVent BioPharma
Mar 23, 2026
Maintains: Buy
Price Target: $37 → $45
Current: $25.46
Upside: +76.75%
Kymera Therapeutics
Dec 22, 2025
Maintains: Buy
Price Target: $80 → $117
Current: $85.05
Upside: +37.57%
PDS Biotechnology
Nov 25, 2025
Maintains: Buy
Price Target: $5 → $3
Current: $1.08
Upside: +177.78%
ORIC Pharmaceuticals
Nov 18, 2025
Initiates: Peer Perform
Price Target: n/a
Current: $10.15
Upside: -
Nov 18, 2025
Initiates: Peer Perform
Price Target: n/a
Current: $14.93
Upside: -
Nov 18, 2025
Initiates: Peer Perform
Price Target: n/a
Current: $19.95
Upside: -
Nov 18, 2025
Initiates: Peer Perform
Price Target: n/a
Current: $114.83
Upside: -
Nov 18, 2025
Initiates: Peer Perform
Price Target: n/a
Current: $19.67
Upside: -
Nov 18, 2025
Initiates: Outperform
Price Target: $42
Current: $49.96
Upside: -15.93%
Nov 18, 2025
Initiates: Outperform
Price Target: $75
Current: $96.43
Upside: -22.22%
Nov 18, 2025
Initiates: Outperform
Price Target: $110
Current: $117.14
Upside: -6.10%
Jul 30, 2025
Maintains: Buy
Price Target: $9 → $12
Current: $5.17
Upside: +132.11%
May 2, 2025
Maintains: Neutral
Price Target: $17 → $14
Current: $4.94
Upside: +183.40%
Mar 5, 2025
Maintains: Neutral
Price Target: $20 → $24
Current: $29.20
Upside: -17.81%
Feb 18, 2025
Maintains: Buy
Price Target: $5.5 → $3.5
Current: $1.67
Upside: +109.58%
Jan 31, 2025
Maintains: Buy
Price Target: $7 → $9
Current: $5.31
Upside: +69.49%
Jan 30, 2025
Initiates: Buy
Price Target: $10
Current: $4.59
Upside: +117.86%
Sep 20, 2024
Maintains: Buy
Price Target: $85 → $40
Current: $9.80
Upside: +308.16%
Jun 18, 2024
Maintains: Buy
Price Target: $9 → $3
Current: $2.75
Upside: +9.09%
May 9, 2024
Downgrades: Neutral
Price Target: $25 → $20
Current: $14.95
Upside: +33.78%
Dec 12, 2023
Downgrades: Neutral
Price Target: $90 → $30
Current: $4.10
Upside: +631.71%
Jul 25, 2023
Maintains: Buy
Price Target: $34 → $36
Current: $24.44
Upside: +47.30%
Nov 11, 2022
Downgrades: Neutral
Price Target: $270 → $90
Current: $1.39
Upside: +6,374.82%
Sep 22, 2022
Maintains: Buy
Price Target: $21 → $18
Current: $2.72
Upside: +561.76%
Jul 19, 2022
Maintains: Buy
Price Target: $6 → $5
Current: $1.13
Upside: +342.48%
Jan 24, 2022
Maintains: Buy
Price Target: $240 → $100
Current: $11.04
Upside: +805.80%
Sep 3, 2021
Downgrades: Neutral
Price Target: $75
Current: $35.09
Upside: +113.74%